Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results